ACP: Muscle-Related Loss Often Exceeds Benchmarks With Incretin-Based Therapies
Medically reviewed by Drugs.com
via HealthDay FRIDAY, April 17, 2026 -- In many incretin-based interventions, reductions in muscle-related indices exceed prespecified benchmarks, according to a review published online April 17 in the Annals of Internal Medicine to coincide with the Internal Medicine Meeting, the annual meeting of the American College of Physicians, held from April 16 to 18 in San Francisco.
John A. Batsis, M.D., from the University of North Carolina at Chapel Hill School of Medicine, and colleagues examined body composition changes associated with incretin therapies (of interest were liraglutide, semaglutide, tirzepatide, and dulaglutide) in adults with obesity in a systematic review including 36 studies (median of 71 participants).
The researchers found that weight loss was consistently larger in the incretin intervention versus the placebo or lifestyle intervention comparator groups and was accompanied by a decrease in total fat mass and visceral adiposity. There was wide variation in the degree of muscle-based losses. Across agents and measurement methods within the incretin groups, the median proportion of total weight loss attributable to reductions in muscle-based indices was 34.9 percent; 68 percent of studies exceeded the benchmark of about 25 percent. The median was about 34.9 percent of total weight loss in studies using bioelectrical impedance analysis or dual-energy X-ray absorptiometry, with 65 percent exceeding the 25 percent benchmark; the median was about 35.8 percent in studies using computed tomography or magnetic resonance imaging, with all studies exceeding the 15 percent benchmark. The 14 studies reporting weight loss in the lifestyle or placebo comparator groups accounted for −2.4 percent median weight loss, 50 percent of which exceeded the respective benchmark.
"Although current and emerging therapies demonstrate promising efficacy, their pleiotropic effects on body composition extend beyond fat reduction and require careful study," the authors write.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2026-04-18 09:00
Read more
- Endotracheal Poractant Alfa Not Effective in Critical Bronchiolitis
- U.S. FDA Approves Label Update to Accelerate Thaw Time for Adstiladrin (nadofaragene firadenovec-vncg)
- EBC: Polyurethane-Coated Implants for Breast Reconstruction Tied to Lower Complication Risk
- New White House Budget Plan Would Reduce HHS Funding by Billions
- Very High Prenatal PFAS Exposure Linked to Childhood Asthma
- Global Maternal Mortality Ratio Reported at 190.5 Deaths/100,000 Livebirths in 2023
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions